Edition:
India

Cardinal Health Inc (CAH.N)

CAH.N on New York Stock Exchange

69.31USD
23 Feb 2018
Change (% chg)

$1.48 (+2.18%)
Prev Close
$67.83
Open
$68.21
Day's High
$69.60
Day's Low
$68.09
Volume
384,601
Avg. Vol
858,721
52-wk High
$84.13
52-wk Low
$54.67

Select another date:

Tue, Feb 20 2018

UPDATE 1-Kentucky accuses Cardinal Health of contributing to opioid epidemic

Feb 19 Kentucky's attorney general on Monday filed a lawsuit against drug distributor Cardinal Health Inc , accusing it of contributing to the opioid epidemic by failing to halt or report suspiciously large or frequent orders by pharmacies of prescription painkillers.

Kentucky accuses Cardinal Health of contributing to opioid epidemic

Feb 19 Kentucky's attorney general on Monday accused the drug distributor Cardinal Health Inc of contributing to the opioid epidemic by failing to halt or report suspiciously large or frequent orders by pharmacies of prescription painkillers.

BRIEF-Barrow, Hanley, Mewhinney & Strauss, Llc Reports 5.68 Percent Passive Stake In Cardinal Health Inc As Of December 31, 2017

* BARROW, HANLEY, MEWHINNEY & STRAUSS, LLC REPORTS 5.68 PERCENT PASSIVE STAKE IN CARDINAL HEALTH INC AS OF DECEMBER 31, 2017 - SEC FILING‍​ Source text (http://bit.ly/2CfIHSC) Further company coverage:

UPDATE 3-Cardinal Health profit beats on CVS tie-up, Medtronic unit buy

* Shares up nearly 5 pct (Adds comments from conference call, analyst comments, background, share movement)

BRIEF-Cardinal Health Reports Q2 Adj. Earnings Per Share $1.31

* CARDINAL HEALTH REPORTS SECOND-QUARTER RESULTS FOR FISCAL YEAR 2018

Cardinal Health's quarterly profit surges

Feb 8 Cardinal Health said on Thursday its quarterly profit more than tripled due to a benefit related to recent changes in U.S. tax laws.

BRIEF-Cardinal Health Adds Akhil Johri To Its Board Of Directors

* CARDINAL HEALTH INC - WITH JOHRI'S ADDITION, BOARD WILL CONSIST OF THIRTEEN DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-Cordis And Medinol Announce FDA Approval Of EluNIR Drug-Eluting Stent System

* CORDIS AND MEDINOL ANNOUNCE FDA APPROVAL OF THE INNOVATIVE ELUNIR DRUG-ELUTING STENT SYSTEM Source text for Eikon: Further company coverage:

UPDATE 3-Shanghai Pharma buys U.S. Cardinal Health's China business for $557 mln

* Cardinal Health put business up for sale due to rule changes

Shanghai Pharma buys U.S. Cardinal Health's China business for $557 mln

Nov 15 State-owned Shanghai Pharmaceuticals Holding Co has agreed to acquire Cardinal Health Inc's China business, one of the nation's largest drug distributors, for $557 million.

Select another date: